Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer Study
By Daniella Parra Lisata Therapeutics (Nasdaq: LSTA) said a study led by The University of Kansas Cancer Center, is testing Lisata’s investigational peptide certepetide with FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers. In 35 PDAC patients treated, the combination was...